ACADIA Pharmaceuticals (ACAD) Competitors

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Do analysts rate ACAD or GMAB?

ACADIA Pharmaceuticals presently has a consensus target price of $28.88, indicating a potential upside of 10.08%. Genmab A/S has a consensus target price of $37.60, indicating a potential upside of 49.74%. Given Genmab A/S's stronger consensus rating and higher probable upside, analysts plainly believe Genmab A/S is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Which has better valuation and earnings, ACAD or GMAB?

Genmab A/S has higher revenue and earnings than ACADIA Pharmaceuticals. Genmab A/S is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$1.02B	4.34	$226.45M	$1.33	19.72
Genmab A/S	$3.12B	5.16	$1.14B	$1.99	12.62

Does the media favor ACAD or GMAB?

In the previous week, ACADIA Pharmaceuticals had 8 more articles in the media than Genmab A/S. MarketBeat recorded 13 mentions for ACADIA Pharmaceuticals and 5 mentions for Genmab A/S. ACADIA Pharmaceuticals' average media sentiment score of 1.13 beat Genmab A/S's score of 0.58 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Do institutionals & insiders believe in ACAD or GMAB?

96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 26.5% of ACADIA Pharmaceuticals shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has more risk and volatility, ACAD or GMAB?

ACADIA Pharmaceuticals has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.

Is ACAD or GMAB more profitable?

Genmab A/S has a net margin of 37.53% compared to ACADIA Pharmaceuticals' net margin of 21.80%. Genmab A/S's return on equity of 21.03% beat ACADIA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	21.80%	14.69%	9.41%
Genmab A/S	37.53%	21.03%	16.98%

Summary

Genmab A/S beats ACADIA Pharmaceuticals on 10 of the 16 factors compared between the two stocks.